Sichuan Hebang Biotechnology Corporation Limited
603077.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | CN¥2,005 | CN¥2,195 | CN¥1,726 | CN¥1,734 |
| % Growth | -8.6% | 27.2% | -0.5% | – |
| Cost of Goods Sold | CN¥1,710 | CN¥2,016 | CN¥1,541 | CN¥1,926 |
| Gross Profit | CN¥295 | CN¥180 | CN¥185 | -CN¥192 |
| % Margin | 14.7% | 8.2% | 10.7% | -11.1% |
| R&D Expenses | CN¥4 | CN¥4 | CN¥5 | CN¥8 |
| G&A Expenses | CN¥0 | CN¥83 | CN¥98 | CN¥98 |
| SG&A Expenses | CN¥130 | CN¥107 | CN¥117 | CN¥123 |
| Sales & Mktg Exp. | CN¥0 | CN¥24 | CN¥18 | CN¥25 |
| Other Operating Expenses | CN¥24 | CN¥34 | CN¥43 | -CN¥1 |
| Operating Expenses | CN¥158 | CN¥145 | CN¥164 | CN¥130 |
| Operating Income | CN¥138 | CN¥35 | CN¥21 | -CN¥322 |
| % Margin | 6.9% | 1.6% | 1.2% | -18.6% |
| Other Income/Exp. Net | -CN¥22 | -CN¥0 | -CN¥0 | -CN¥3 |
| Pre-Tax Income | CN¥115 | CN¥34 | CN¥21 | -CN¥325 |
| Tax Expense | CN¥79 | CN¥2 | CN¥13 | -CN¥59 |
| Net Income | CN¥41 | CN¥39 | CN¥13 | -CN¥190 |
| % Margin | 2.1% | 1.8% | 0.7% | -11% |
| EPS | 0.005 | 0.005 | 0.002 | -0.024 |
| % Growth | 4% | 212.5% | 106.8% | – |
| EPS Diluted | 0.004 | 0.004 | 0.001 | -0.02 |
| Weighted Avg Shares Out | 7,974 | 7,823 | 7,823 | 8,052 |
| Weighted Avg Shares Out Dil | 10,334 | 10,431 | 10,431 | 9,468 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥16 | CN¥15 | CN¥11 | CN¥18 |
| Interest Expense | CN¥29 | CN¥29 | CN¥28 | CN¥7 |
| Depreciation & Amortization | CN¥0 | CN¥239 | CN¥244 | CN¥244 |
| EBITDA | CN¥148 | CN¥275 | CN¥289 | -CN¥107 |
| % Margin | 7.4% | 12.5% | 16.7% | -6.2% |